Phase 2 study of neoadjuvant enzalutamide and paclitaxel for luminal androgen receptor-enriched TNBC: Trial results and insights into "ARness".
Cell Rep Med
; 5(6): 101595, 2024 Jun 18.
Article
en En
| MEDLINE
| ID: mdl-38838676
ABSTRACT
Luminal androgen receptor (LAR)-enriched triple-negative breast cancer (TNBC) is a distinct subtype. The efficacy of AR inhibitors and the relevant biomarkers in neoadjuvant therapy (NAT) are yet to be determined. We tested the combination of the AR inhibitor enzalutamide (120 mg daily by mouth) and paclitaxel (80 mg/m2 weekly intravenously) (ZT) for 12 weeks as NAT for LAR-enriched TNBC. Eligibility criteria included a percentage of cells expressing nuclear AR by immunohistochemistry (iAR) of at least 10% and a reduction in sonographic volume of less than 70% after four cycles of doxorubicin and cyclophosphamide. Twenty-four patients were enrolled. Ten achieved a pathologic complete response or residual cancer burden-I. ZT was safe, with no unexpected side effects. An iAR of at least 70% had a positive predictive value of 0.92 and a negative predictive value of 0.97 in predicting LAR-enriched TNBC according to RNA-based assays. Our data support future trials of AR blockade in early-stage LAR-enriched TNBC.
Palabras clave
Texto completo:
1
Base de datos:
MEDLINE
Asunto principal:
Feniltiohidantoína
/
Benzamidas
/
Protocolos de Quimioterapia Combinada Antineoplásica
/
Receptores Androgénicos
/
Paclitaxel
/
Terapia Neoadyuvante
/
Neoplasias de la Mama Triple Negativas
/
Nitrilos
Límite:
Adult
/
Aged
/
Female
/
Humans
/
Middle aged
Idioma:
En
Revista:
Cell Rep Med
Año:
2024
Tipo del documento:
Article